Literature DB >> 25934760

The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection.

Mahmoud Abu-Amara1, Orlando Cerocchi1, Gurtej Malhi1, Suraj Sharma1, Colina Yim1, Hemant Shah1, David K Wong1, Harry L A Janssen1, Jordan J Feld1.   

Abstract

BACKGROUND: Patients with chronic hepatitis B (CHB) infection are at an increased risk of developing hepatocellular carcinoma (HCC). Risk scores have been developed in Asian populations to predict HCC risk over time. AIM: To assess the performance of HCC risk prediction models in a heterogeneous population of patients with CHB.
METHODS: Scores were calculated at baseline using CU-HCC, REACH-B, NGM1-HCC, NGM2-HCC and GAG-HCC models and the incidence of HCC was determined. The predictive ability of each score was evaluated using the area under the receiver operating characteristic curve (AUROC), Cox regression and plots of observed versus predicted HCC. The predictive value of the scores was compared between Asian and non-Asian patients and between cirrhotic versus non-cirrhotic with and without treatment.
RESULTS: Of 2105 patients, 70 developed HCC. Increasing risk score was associated with HCC in all models. The CU-HCC model had the highest AUROC in Asian (0.85) and non-Asian (0.91) patients. Patients identified as low risk by any model had a very low incidence of HCC (0-0.15 per year), with the highest proportion of patients identified as low risk using CU-HCC (67%) or GAG-HCC (78%). The risk of HCC was similar to predicted for low-risk and medium-risk patients but was lower than predicted for high-risk patients. Treated patients had a lower than predicted risk of HCC, particularly in non-cirrhotic high-risk patients with longer follow-up.
CONCLUSIONS: Although all models predicted the risk of HCC, models that incorporated parameters of liver function or cirrhosis (CU-HCC/GAG-HCC) were most accurate. Low-risk patients likely require reduced HCC surveillance. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  HEPATITIS B; HEPATOCELLULAR CARCINOMA

Mesh:

Year:  2015        PMID: 25934760     DOI: 10.1136/gutjnl-2014-309099

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

Review 1.  Liver cancer screening in high-risk populations.

Authors:  Morris Sherman
Journal:  Hepat Oncol       Date:  2015-11-30

2.  Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk.

Authors:  Yang Yang; Jing Gao; Yu-Ting Tan; Hong-Lan Li; Jing Wang; Xiao Ma; Wei Zheng; Xiao-Ou Shu; Yong-Bing Xiang
Journal:  J Gastroenterol Hepatol       Date:  2018-02-05       Impact factor: 4.029

Review 3.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

4.  Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Authors:  Alexander Gerbes; Fabien Zoulim; Herbert Tilg; Jean-François Dufour; Jordi Bruix; Valérie Paradis; Riad Salem; Markus Peck-Radosavljevic; Peter R Galle; Tim F Greten; Jean-Charles Nault; Matias A Avila
Journal:  Gut       Date:  2017-11-17       Impact factor: 23.059

Review 5.  Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.

Authors:  Hye Won Lee; Sang Hoon Ahn
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

6.  Clonorchis sinensis infection and co-infection with the hepatitis B virus are important factors associated with cholangiocarcinoma and hepatocellular carcinoma.

Authors:  Yunliang Shi; Zhihua Jiang; Yichao Yang; Peiqiu Zheng; Haiyan Wei; Yuan Lin; Guoli Lv; Qingli Yang
Journal:  Parasitol Res       Date:  2017-08-12       Impact factor: 2.289

Review 7.  How to improve HCC surveillance outcomes.

Authors:  Morris Sherman
Journal:  JHEP Rep       Date:  2019-11-05

Review 8.  Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk.

Authors:  Naoto Kubota; Naoto Fujiwara; Yujin Hoshida
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

9.  Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.

Authors:  Joseph K Hoang; Hwai-I Yang; An Le; Nghia H Nguyen; Derek Lin; Vinh D Vu; Kevin Chaung; Vincent Nguyen; Huy N Trinh; Jiayi Li; Jian Q Zhang; Chien-Jen Chen; Mindie H Nguyen
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 10.  Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Richard A Burkhart; Timothy M Pawlik
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.